USA - NASDAQ:ONCO - US68237Q2030 - Common Stock
The current stock price of ONCO is 3.1 USD. In the past month the price increased by 5.8%. In the past year, price decreased by -55.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.55 | 384.42B | ||
AMGN | AMGEN INC | 12.58 | 147.73B | ||
GILD | GILEAD SCIENCES INC | 14.54 | 139.64B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.21 | 100.82B | ||
REGN | REGENERON PHARMACEUTICALS | 12.55 | 60.69B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.45B | ||
ARGX | ARGENX SE - ADR | 81.64 | 46.32B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.81 | 39.50B | ||
INSM | INSMED INC | N/A | 30.26B | ||
NTRA | NATERA INC | N/A | 23.63B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.53B | ||
BIIB | BIOGEN INC | 8.95 | 21.01B |
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 5
Phone: 15136204101
The current stock price of ONCO is 3.1 USD. The price increased by 1.64% in the last trading session.
The exchange symbol of ONCONETIX INC is ONCO and it is listed on the Nasdaq exchange.
ONCO stock is listed on the Nasdaq exchange.
ONCONETIX INC (ONCO) has a market capitalization of 4.80M USD. This makes ONCO a Nano Cap stock.
ONCONETIX INC (ONCO) currently has 5 employees.
ONCONETIX INC (ONCO) has a support level at 2.67 and a resistance level at 3.1. Check the full technical report for a detailed analysis of ONCO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONCO does not pay a dividend.
ONCONETIX INC (ONCO) will report earnings on 2025-12-08.
ONCONETIX INC (ONCO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-593.67).
The outstanding short interest for ONCONETIX INC (ONCO) is 5.11% of its float. Check the ownership tab for more information on the ONCO short interest.
ChartMill assigns a technical rating of 1 / 10 to ONCO. When comparing the yearly performance of all stocks, ONCO is a bad performer in the overall market: 95.88% of all stocks are doing better.
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -593.67. The EPS increased by 93.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -240.02% | ||
ROE | -722.3% | ||
Debt/Equity | 1.37 |